Merck KGaA (MRK) - Net Assets

Latest as of September 2025: €29.00 Billion EUR ≈ $33.90 Billion USD

Based on the latest financial reports, Merck KGaA (MRK) has net assets worth €29.00 Billion EUR (≈ $33.90 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€50.93 Billion ≈ $59.54 Billion USD) and total liabilities (€21.93 Billion ≈ $25.63 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Merck KGaA liquidity resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€29.00 Billion
% of Total Assets	56.94%
Annual Growth Rate	12.96%
5-Year Change	76.22%
10-Year Change	133.27%
Growth Volatility	26.07

Merck KGaA - Net Assets Trend (2002–2024)

This chart illustrates how Merck KGaA's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Merck KGaA for the complete picture of this company's asset base.

Annual Net Assets for Merck KGaA (2002–2024)

The table below shows the annual net assets of Merck KGaA from 2002 to 2024. For live valuation and market cap data, see how much is Merck KGaA worth.

Year	Net Assets	Change
2024-12-31	€29.99 Billion ≈ $35.06 Billion	+12.08%
2023-12-31	€26.75 Billion ≈ $31.28 Billion	+2.88%
2022-12-31	€26.00 Billion ≈ $30.40 Billion	+21.43%
2021-12-31	€21.42 Billion ≈ $25.04 Billion	+25.85%
2020-12-31	€17.02 Billion ≈ $19.89 Billion	-5.00%
2019-12-31	€17.91 Billion ≈ $20.94 Billion	+3.95%
2018-12-31	€17.23 Billion ≈ $20.15 Billion	+22.52%
2017-12-31	€14.07 Billion ≈ $16.44 Billion	+0.11%
2016-12-31	€14.05 Billion ≈ $16.43 Billion	+9.29%
2015-12-31	€12.86 Billion ≈ $15.03 Billion	+8.93%
2014-12-31	€11.80 Billion ≈ $13.80 Billion	+6.61%
2013-12-31	€11.07 Billion ≈ $12.94 Billion	+6.28%
2012-12-31	€10.41 Billion ≈ $12.18 Billion	-0.75%
2011-12-31	€10.49 Billion ≈ $12.27 Billion	+1.17%
2010-12-31	€10.37 Billion ≈ $12.13 Billion	+9.02%
2009-12-31	€9.51 Billion ≈ $11.12 Billion	-1.11%
2008-12-31	€9.62 Billion ≈ $11.25 Billion	+10.74%
2007-12-31	€8.69 Billion ≈ $10.16 Billion	+128.18%
2006-12-31	€3.81 Billion ≈ $4.45 Billion	+14.37%
2005-12-31	€3.33 Billion ≈ $3.89 Billion	+15.00%
2004-12-31	€2.89 Billion ≈ $3.38 Billion	+22.52%
2003-12-31	€2.36 Billion ≈ $2.76 Billion	+15.06%
2002-12-31	€2.05 Billion ≈ $2.40 Billion	--

Equity Component Analysis

This analysis shows how different components contribute to Merck KGaA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 2208600000000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	€22.09 Billion	73.84%
Common Stock	€565.00 Million	1.89%
Other Comprehensive Income	€3.11 Billion	10.41%
Other Components	€4.15 Billion	13.86%
Total Equity	€29.91 Billion	100.00%

Merck KGaA Competitors by Market Cap

The table below lists competitors of Merck KGaA ranked by their market capitalization.

Company	Market Cap
KGHM Polska Miedz SA WAR:KGH	$16.67 Billion
TELENOR ASA SP.ADR/ O.N. F:TEQA	$16.69 Billion
BE SEMICON.INDS NY EO091 F:BSIA	$16.74 Billion
Hologic Inc NASDAQ:HOLX	$16.77 Billion
Brookfield Infrastructure Partners LP NYSE:BIP	$16.63 Billion
Rede D'Or São Luiz S.A. SA:RDOR3	$16.61 Billion
Affirm Holdings Inc NASDAQ:AFRM	$16.59 Billion
STRAUM.HLD.UNSP.ADR/1/10 F:QS50	$16.59 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Merck KGaA's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 26,680,000,000 to 29,912,000,000, a change of 3,232,000,000 (12.1%).
Net income of 2,777,000,000 contributed positively to equity growth.
Dividend payments of 284,000,000 reduced retained earnings.
Other comprehensive income increased equity by 1,447,000,000.
Other factors decreased equity by 708,000,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	€2.78 Billion	+9.28%
Dividends Paid	€284.00 Million	-0.95%
Other Comprehensive Income	€1.45 Billion	+4.84%
Other Changes	€-708.00 Million	-2.37%
Total Change	€-	12.11%

Book Value vs Market Value Analysis

This analysis compares Merck KGaA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.60x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 19.10x to 1.60x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2002-12-31	€5.76	€110.05	x
2003-12-31	€6.36	€110.05	x
2004-12-31	€7.41	€110.05	x
2005-12-31	€8.32	€110.05	x
2006-12-31	€9.67	€110.05	x
2007-12-31	€19.98	€110.05	x
2008-12-31	€21.86	€110.05	x
2009-12-31	€21.76	€110.05	x
2010-12-31	€23.76	€110.05	x
2011-12-31	€24.03	€110.05	x
2012-12-31	€23.86	€110.05	x
2013-12-31	€25.39	€110.05	x
2014-12-31	€26.99	€110.05	x
2015-12-31	€29.36	€110.05	x
2016-12-31	€32.20	€110.05	x
2017-12-31	€32.20	€110.05	x
2018-12-31	€39.56	€110.05	x
2019-12-31	€41.09	€110.05	x
2020-12-31	€38.98	€110.05	x
2021-12-31	€49.08	€110.05	x
2022-12-31	€59.63	€110.05	x
2023-12-31	€61.36	€110.05	x
2024-12-31	€68.80	€110.05	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Merck KGaA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 9.28%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 13.13%
• Asset Turnover: 0.41x
• Equity Multiplier: 1.72x
Recent ROE (9.28%) is below the historical average (13.16%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2002	10.69%	2.91%	0.99x	3.73x	€13.88 Million
2003	9.33%	3.02%	1.03x	2.99x	€-15.66 Million
2004	23.55%	12.58%	0.93x	2.01x	€386.61 Million
2005	20.53%	11.46%	0.81x	2.22x	€345.03 Million
2006	26.68%	16.00%	0.77x	2.16x	€625.97 Million
2007	40.81%	49.88%	0.47x	1.73x	€2.66 Billion
2008	3.99%	5.02%	0.48x	1.65x	€-571.44 Million
2009	3.98%	4.86%	0.46x	1.77x	€-569.31 Million
2010	6.21%	6.90%	0.41x	2.17x	€-391.48 Million
2011	6.02%	6.12%	0.46x	2.12x	€-415.71 Million
2012	5.47%	5.07%	0.52x	2.09x	€-469.44 Million
2013	10.91%	10.84%	0.53x	1.89x	€100.20 Million
2014	9.86%	10.06%	0.44x	2.22x	€-16.86 Million
2015	8.72%	8.68%	0.34x	2.97x	€-163.95 Million
2016	11.64%	10.84%	0.39x	2.73x	€230.10 Million
2017	18.57%	16.96%	0.43x	2.54x	€1.20 Billion
2018	19.62%	22.74%	0.40x	2.14x	€1.65 Billion
2019	7.39%	8.17%	0.37x	2.45x	€-466.50 Million
2020	11.73%	11.33%	0.42x	2.47x	€292.40 Million
2021	14.32%	15.52%	0.43x	2.13x	€921.20 Million
2022	12.83%	14.96%	0.46x	1.87x	€733.30 Million
2023	10.58%	13.45%	0.43x	1.82x	€156.00 Million
2024	9.28%	13.13%	0.41x	1.72x	€-214.20 Million

Industry Comparison

This section compares Merck KGaA's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $778,651,241
Average return on equity (ROE) among peers: -82.08%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Merck KGaA (MRK)	€29.00 Billion	10.69%	0.76x	$16.63 Billion
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ)	$6.51 Billion	11.81%	0.39x	$635.99 Million
AYURCANN HOLDINGS CORP. (3ZQ0)	$534.88K	-741.80%	26.77x	$113.81K
LORDS CO. WORLDW. HOLD. (4XM)	$-1.01 Million	0.00%	0.00x	$134.78K
EQL PHARMA AB (7JK)	$154.75 Million	19.98%	0.85x	$148.83 Million
Alkermes plc (8AK)	$1.07 Billion	1.94%	0.48x	$5.00 Billion
OPTIMI HEALTH CORP. (8BN)	$9.58 Million	-63.03%	0.52x	$17.99 Million
LABIANA HEALTH S.A.EO-10 (8RK)	$2.57 Million	9.87%	19.25x	$40.60 Million
CANNABIS POLAND AB ZY-10 (8TE)	$3.54 Million	-57.78%	0.18x	$1.75 Million
Apontis Pharma AG (APPH)	$40.71 Million	-1.83%	0.33x	$91.63 Million
CRAFTPORT CANNABIS CORP. (BBW0)	$-3.18 Million	0.00%	0.00x	$1.45 Million

About Merck KGaA

XETRA:MRK Germany Drug Manufacturers - Specialty & Generic

Market Cap

$16.63 Billion

€14.22 Billion EUR

Market Cap Rank

#1482 Global

#330 in Germany

Share Price

€110.05

Change (1 day)

+1.71%

52-Week Range

€102.80 - €130.00

All Time High

€220.61